ECM
TGTX icon

Everence Capital Management’s TG Therapeutics TGTX Stock Holding History

Everence Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
+4,624
New +$189K 0.01% 711
2025
Q4 		– Sell
-5,850
Closed -$211K – 837
2025
Q3 		$211K Hold
5,850
– – 0.01% 756
2025
Q2 		$211K Hold
5,850
– – 0.01% 736
2025
Q1 		$231K Buy
+5,850
New +$197K 0.02% 690
2024
Q4 		– Sell
-16,260
Closed -$380K – 1025
2024
Q3 		$380K Buy
+16,260
New +$355K 0.02% 508

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Everence Capital Management's TGTX Position: Q2 2026 in Review

Everence Capital Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,624 shares worth $254K. The stake represents 0.01% of the portfolio and ranks #711 among its holdings. This is a return to the name: Everence Capital Management previously reported a position in TGTX as recently as Q3 2025.

Everence Capital Management first reported a position in TGTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $380K in Q3 2024. 193 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Everence Capital Management held 4,624 shares of TG Therapeutics worth $254K as of Q2 2026.
  • TG Therapeutics was a new Everence Capital Management position in Q2 2026.
  • TG Therapeutics made up 0.01% of Everence Capital Management's portfolio in Q2 2026, its #711 holding.
  • Everence Capital Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Everence Capital Management's TG Therapeutics position peaked at $380K in Q3 2024.
  • 193 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.